Legal & General Group
VTGN icon

Legal & General Group’s VistaGen Therapeutics VTGN Stock Holding History

Legal & General Group’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-690
Closed -$2.58K – 3523
2023
Q1 		$2.58K Hold
690
– – ﹤0.01% 3342
2022
Q4 		$2.14K Hold
690
– – ﹤0.01% 3391
2022
Q3 		$3K Sell
690
-82
-11% -$813 ﹤0.01% 3426
2022
Q2 		$20K Buy
772
+117
+18% +$4.13K ﹤0.01% 3244
2022
Q1 		$24K Hold
655
– – ﹤0.01% 3197
2021
Q4 		$38K Buy
655
+7
+1% +$456 ﹤0.01% 3093
2021
Q3 		$53K Hold
648
– – ﹤0.01% 2963
2021
Q2 		$61K Buy
+648
New +$48K ﹤0.01% 2888

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group's VTGN Position: Q2 2023 in Review

Legal & General Group sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 690 shares — an estimated $2.58K sold.

Legal & General Group first reported a position in VTGN in Q2 2021 and held it in 8 quarters. The position peaked at $61K in Q2 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • Legal & General Group reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Legal & General Group sold 690 VistaGen Therapeutics shares in Q2 2023, an estimated $2.58K.
  • Legal & General Group first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 8 quarters.
  • Legal & General Group's VistaGen Therapeutics position peaked at $61K in Q2 2021.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.